PD-L1 expression of 742 newly diagnosed advanced respiratory and digestive system tumours in China based on SP142 assay.

被引：0
|
作者：
Chen, Yanhui
Wang, Yating
Yang, Bohang
Hu, Ying
Zeng, Hui
Zhang, Henghui
机构：
[1] Capital Med Univ, Beijing Ditan Hosp, Inst Infect Dis, Lab Emerging Infect Dis, Beijing, Peoples R China
[2] Genecast Precis Med Technol Inst, Beijing, Peoples R China
[3] Capital Med Univ, Beijing Key Lab Emerging Infect Dis, Inst Infect Dis, Beijing Ditan Hosp, Beijing, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.e24298
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e24298
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Assessment of concordance among 22C3, SP263, and SP142 immunohistochemistry assay for PD-L1 expression in non-small cell lung cancer.
    Jung, Chi Young
    Kim, Eun Jin
    Sung, Woo Jung
    CANCER IMMUNOLOGY RESEARCH, 2020, 8 (04) : 41 - 42
  • [32] Relationship between SP142 PD-L1 Expression and 18F-FDG Uptake in Non-Small-Cell Lung Cancer
    Zhao, Long
    Liu, Jinjun
    Shi, Jingyun
    Wang, Huoqiang
    CONTRAST MEDIA & MOLECULAR IMAGING, 2020, 2020
  • [33] A budget impact analysis of the VENTANA PD-L1 SP142 immunohistochemistry assay versus the Dako PD-L1 IHC 22C3 assay in patients with advanced or metastatic triple-negative breast cancer treated with atezolizumab in combination with nab-paclitaxel
    Scatena, Cristian
    Ravasio, Roberto
    Raimondo, Paola
    Giuliano, Mario
    FARMECONOMIA-HEALTH ECONOMICS AND THERAPEUTIC PATHWAYS, 2021, 22 (01)
  • [34] Comparison of SP142 (Ventana) and SP263 (Ventana) assays to test PD-L1 expression in metastatic cancer patients to be treated with immune checkpoint inhibitors.
    Oyan, Basak
    Sonmez, Ozlem
    Yazar, Aziz
    Teomet, Mehmet
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [35] PD-L1 Expression, Using SP142 and 22C3 Antibody Clones, in NSCLC Patients with Known Status of EGFR and ALK Genes
    Kucharczyk, T.
    Krawczyk, P.
    Jarosz, B.
    Grenda, A.
    Reszka, K.
    Pankowski, J.
    Wojas-Krawczyk, K.
    Nicos, M.
    Szumilo, J.
    Trojanowski, T.
    Milanowski, J.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2373 - S2373
  • [36] Assessment of PD-L1 Expression in Tumor Microenvironment of Mismatch Repair Deficient Colon Cancer: Comparing Two Antibody Clones, SP142 vs. SP263
    Chen, Zongming E.
    Bitting, Angela
    Lin, Fan
    LABORATORY INVESTIGATION, 2017, 97 : 165A - 165A
  • [37] Assessment of PD-L1 Expression in Tumor Microenvironment of Mismatch Repair Deficient Colon Cancer: Comparing Two Antibody Clones, SP142 vs. SP263
    Chen, Zongming E.
    Bitting, Angela
    Lin, Fan
    MODERN PATHOLOGY, 2017, 30 : 165A - 165A
  • [38] Clinical and pathologic features associated with PD-L1 (SP142) expression in stromal tumor-infiltrating immune cells of triple-negative breast carcinoma
    Hoda, Raza Syed
    Brogi, Edi
    Dos Anjos, Carlos Henrique
    Grabenstetter, Anne
    Ventura, Katia
    Patil, Sujata
    Selenica, Pier
    Weigelt, Britta
    Reis-Filho, Jorge Sergio
    Traina, Tiffany
    Robson, Mark
    Norton, Larry
    Wen, Hannah Yong
    MODERN PATHOLOGY, 2020, 33 (11) : 2221 - 2232
  • [39] Concordance of IHC and a new blood -based expression assay for the detection of PD-L1 in patients diagnosed with NSCLC
    Pritchett, Michael A.
    Niu, Jiaxin
    Jackson, Leisa
    Mellert, Hestia
    Pestano, Gary A.
    MOLECULAR CANCER THERAPEUTICS, 2018, 17 (01)
  • [40] Evaluation of PD-L1 expression in various formalin-fixed paraffin embedded tumour tissue samples using SP263, SP142 and QR1 antibody clones
    Kubelka-Sabit, K.
    Jashar, D.
    Filipovski, V.
    Kondeva, M.
    VIRCHOWS ARCHIV, 2022, 481 (SUPPL 1) : S307 - S307
12345